KBI Biopharma and Selexis Hold Joint Ribbon Cutting of the Expanded State-of-the-Art Facility in Geneva, Switzerland
KBI Biopharma SA (KBI) and Selexis SA, both JSR Life Sciences companies, held a joint ribbon-cutting ceremony yesterday at their new state-of-the-art facility in Geneva, Switzerland. Designed to directly serve the increased demand for biopharmaceutical drug development and manufacturing in Europe, the facility will support an integrated, end-to-end process of Selexis’ cell line development (CLD) services along with KBI’s contract development and manufacturing services for industry clients throughout the immediate region and beyond.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005082/en/
KBI Biopharma and Selexis ribbon cutting at their new state-of-the-art facility in Geneva, Switzerland, Tuesday, July 5, 2022 (from left to right: Mark Lutgen, KBI Biopharma, VP of Global Engineering; Mario Rodriguez, Mayor, Plan-les-Ouates; Fabienne Fischer, State Councilor and Head of the Department of the Economy and Employment; Mark W. Womack, KBI Biopharma and Selexis, Chief Executive Officer; Tim Lowery, President, JSR Life Sciences) (Photo: Business Wire)
As demand for innovative biologics and effective biosimilars to treat cancer, infectious diseases, and autoimmune diseases continue to rise in Europe and around the world, developing and manufacturing these and other therapeutics, remains complex and time-consuming. By co-locating in one facility, KBI and Selexis will deliver trusted, streamlined, and cost-effective solutions to help clients confidently advance their investigational therapies.
“The opening of our Geneva facility last month was a major milestone for KBI and Selexis, and we are excited to come together today and commemorate this great achievement,” said Mark W. Womack, CEO of KBI and Selexis. “KBI and Selexis have a long history of success together. Our collaboration has accelerated more than 60 drug development programs in Europe and worldwide. Integrating Selexis’ world-renowned CLD services with KBI’s process development innovation and excellence, as well as clinical and commercial manufacturing experience provides our clients with seamless, cost-effective, and reliable development and manufacturing for their products. Our aim has always been to help our clients bring novel and effective therapies to the clinic and the market faster. This facility will help advance that mission.”
The ~94,000 square-foot facility will house new laboratories to support Selexis’ unique technical cell line workflows and KBI’s process development and cGMP manufacturing and quality control with a suite of analytical testing laboratories and cGMP single-use manufacturing trains. The expansion will generate over 300 positions in development, operations, and quality assurance. The ribbon-cutting, held on July 5, was attended by the following:
- Luca Bolliger, VP of the Swiss Biotech Association and President of the Swiss Biotech Success Stories Jury
- Mario Rodriguez, Mayor of Plan-les-Ouates
- Fabienne Fischer, State Councilor - Member of the Geneva government, Head of the economy and employment department (DEE)
“I am delighted with the development of KBI and Selexis' activities in Geneva, which contributes to the development of the life sciences sector in Geneva and reinforces our local ecosystem,” said Councilor Fischer. “It also demonstrates the potential and attractiveness of our region.”
About KBI Biopharma, Inc.
KBI Biopharma SA is a wholly-owned subsidiary of KBI Biopharma, Inc., and a JSR Life Sciences company. KBI Biopharma is a leading global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps clients advance drug candidates into the clinic and beyond. KBI serves its global clients with multiple locations in Europe and the USA. www.kbibiopharma.com
About Selexis SA
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global client partners have utilized Selexis technologies to advance more than 160 drug candidates in preclinical and clinical development and manufacture ten commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220706005082/en/
Contact information
KBI Biopharma Company Inquiries
Aruna Mor
KBI Biopharma, Inc.
amor@kbibiopharma.com
Selexis SA Company Inquiries
Maria-Pilar Gimenez
Selexis SA
maria-pilar.gimenez@selexis.com
KBI Biopharma Media Inquiries
Blair Ciecko
CG Life
bciecko@cglife.com
Selexis SA Media Inquiries
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Riyadh to Host the First Edition of BIO Middle East10.9.2025 21:01:00 EEST | Press release
The Saudi Ministry of Health has announced the launch of the first edition of BIO Middle East, the region’s pioneering event dedicated entirely to biotechnology. The event will take place from May 11 to 13, 2026, co-locating with CPHI Middle East at the Riyadh Exhibition and Convention Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250910348484/en/ Riyadh to Host the First Edition of BIO Middle East (Graphic: AETOSWire) A first of its kind for the region, the event reinforces the Kingdom’s leadership in this fast-growing sector and underscores its commitment to becoming a regional and global hub for pharmaceuticals and life sciences. As part of a global series of landmark BIO gatherings that bring together leaders, innovators, and investors from across the world, BIO Middle East will extend this world-class platform for partnership and innovation to the region for the very first time. The BIO Middle East exhibition a
SingleStore Announces Growth Buyout Led by Vector Capital10.9.2025 20:00:00 EEST | Press release
SingleStore, Inc. (“SingleStore” or the “Company”), the leading data platform for enterprise AI, today announced it has entered into an agreement with Vector Capital Management, L.P. (“Vector”), a private equity firm with a nearly three decade track record leading transformational investments in established technology businesses, in which Vector will lead a growth buyout of SingleStore. Raj Verma, SingleStore’s Chief Executive Officer, and the Company’s established management team, who together have decades of experience in leading fast-growth, AI-first enterprise technology companies, will continue to lead the business. Long-term SingleStore shareholders including Google Ventures, Dell Technologies Capital, IBM, and REV Venture Partners will remain as investors in SingleStore. Several Vector Capital limited partners such as Adams Street Partners, J.P. Morgan Asset Management, the External Investing Group (XIG) at Goldman Sachs Asset Management, Angeles Investments, Lexington Partners,
FIA President Mohammed Ben Sulayem Leads Fight Against Online Abuse, Bringing Global Leaders Together in Stockholm10.9.2025 19:22:00 EEST | Press release
The Fédération Internationale de l'Automobile (FIA), the global governing body for motorsport and the federation for mobility organisations worldwide, has welcomed industry experts and thought leaders to Stockholm, Sweden, for the second global United Against Online Abuse (UAOA) conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250910299906/en/ FIA President and UAOA Founder, Mohammed Ben Sulayem, speaking at the second global United Against Online Abuse (UAOA) conference. Bringing together voices from the world of sport, politics, and social media, the coalition reaffirmed their collective commitment to combatting online abuse, welcoming new members and sharing knowledge, innovation, and tools to accelerate progress in tackling this digital threat. Joined by high-profile attendees united in UAOA’s mission of eradicating online hate and creating a safer digital environment, FIA President and UAOA Founder, Mohammed B
Verimatrix and Velocix Team Up to Fight CDN Piracy10.9.2025 18:45:00 EEST | Press release
Regulatory News: Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced a strategic collaboration with Velocix, the market’s premier carrier-grade CDN software provider, to help streaming providers combat piracy, boost paid video subscriptions, and cut CDN costs. This joint initiative provides streaming providers with the means to detect, deny, and prevent unsanctioned usage of CDN capacity by third parties. CDN leeching, where unauthorized users consume content directly from the network without paying for it, is a critical and costly challenge for video service providers. Verimatrix Streamkeeper™ Counterspy protects the client side, ensuring only legitimate users can access content, by providing string app authentication, protecting content keys, and safeguarding the token exchange. Velocix’s Carrier-Grade CDN and Video Analytics Platform bring powerful server-side features, including advanced tokenization sc
Home-Compostable ButterFresh ™ Parchment Marks New Step in ProAmpac’s Sustainability Journey10.9.2025 18:14:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, proudly announces that its ButterFresh Parchment has earned the OK compost HOME certificate by TÜV AUSTRIA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250910223002/en/ ProAmpac's ButterFresh Parchment has earned the OK compost HOME certificate by TÜV AUSTRIA. ButterFresh Parchment is a wax-free, PFAS non-intent printed butter wrap designed for compostability without compromising performance and runability during the packing step. This parchment protects butter, margarine, and other oil-based solid products with superior grease resistance and excellent dead-fold properties, locking in freshness and reducing air exposure. “Earning the OK compost HOME certificate by TÜV AUSTRIA underscores our commitment to delivering packaging solutions that combine performance, process efficiency, and environmental responsibility,” said Ray Recchia, global innovation ma
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom